John Nicosia
Seminars
Tuesday 18th November 2025
Panel Discussion: What Does Good Look Like for Investors & Pharma? Defining Value & De-Risking Strategies to Attract Investment in Antifibrotics
2:00 pm
As competition and innovation grow across fibrosis indications, clarity on what makes a compelling therapeutic story is more essential than ever. This panel brings together experts to explore how to shape preclinical packages that spark commercial interest and secure partnerships.
Key Discussion Points:
- What types of efficacy, durability, mechanism, safety, and translatability data do investors and pharma want to see at early stages to build confidence?
- Which companies, modalities, and strategies are resonating in the market today, and what differentiates them from the noise?
- How important is timing (first-in-class vs best-in-class), and what role do management teams, clinical strategies, and disease area focus play in the decision to invest or partner?
Monday 17th November 2025
Decoding the Fibrotic Circuitry to Sharpen Discovery with Mechanistic Clarity & Context-Specific Targeting
11:00 am
- 1:00 pm
As antifibrotic drug development evolves, a deeper understanding of the cellular
architecture and communication networks that drive fibrosis is critical. This workshop explores fibroblast biology across indications, highlighting how tissue-specific and conserved mechanisms can better inform early target selection and derisk downstream development.
This workshop will gather experts to discuss:
- Dissecting immune–fibroblast, epithelial–fibroblast, and vascular–fibroblast interactions to uncover common vs divergent signaling mechanisms
- Evaluating the therapeutic implications of context-specific TGF-β inhibition (selective targeting of ECM-bound pro-TGFβ1) and navigating the balance between efficacy and toxicity
- How spatial omics, niche-specific activation cues, and cross-organ learnings are enabling more precise, safer antifibrotic strategies.
